Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up the in-house production of small molecule drugs.
A milestone payment from Bristol-Myers Squibb for the successful advancement of a project into clinical development, along with strong sales by its contract research and manufacturing services unit, prompted Albany Molecular Research Inc (AMRI) to hike...
In the world of chemistry the majority of reactions are well known
and have been around for a very long time producing similar
compounds. It is not very often that a completely new reaction
methodology comes along which can turn something...
Shire and Noven Pharmaceuticals have announced the voluntary
withdrawal of a limited amount of Attention Deficit Hyperactivity
Disorder (ADHD) transdermal patches following reports of a
mechanical problem when applying the patch.
Over half way into the year and the widely held view that the
pharma industry is struggling to produce truly innovative drugs
looks set to continue with fewer drug approvals in the US than this
time last year.
Albany Molecular Research (AMRI) has announced a multi-year drug
substance manufacturing agreement with New River Pharmaceuticals,
as its attention deficit hyperactivity disorder (ADHD) medicine
looks set to hit the market.
Shire, Britain's third-biggest drugmaker, has won approval in the
US for Daytrana, a methylphenidate skin patch developed with
Noven's transdermal technology, making it the first non-oral
medication for the treatment of...
Supernus Pharmaceuticals has acquired the drug formulation business
of Shire Laboratories (SLI) in a move that strengthens the
pharmaceutical technologies and services. The company will make use
of the patents to improve its own portfolio...
Researchers have discovered a new mechanism that reveals how high
levels of a neurotransmitter exerts its effect on the brain. The
findings provide new research avenues to understand and potentially
The manufacturing compliance problems affecting US generic drug
manufacturer Able Laboratories, which have prompted a huge recall
of its entire product range, show little signs of being resolved,
reports Phil Taylor.
Newly discovered serotonin pathways in the nervous system are
providing a path toward future pharmaceutical treatments for
depression and other disorders such as depression, anxiety, sudden
infant death syndrome, attention deficit...
Dermatrends, a US drug delivery company, has been awarded a patent
that covers the method of using bases to enhance the permeation of
amine drugs across the skin and could lead to new products for
Alzheimer's and other diseases.
A once-daily version of a drug for attention deficit problems in
children - originally designed to avoid the stigma of having to
take medication during school hours - could also save lives on the
road, according to new research.